전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved12 programs
CGTStandard DatabasestaleBristol-Myers SquibbPhase 2

Metoprolol (Metoprolol)

Solid Tumor; Hematological Malignancy · Solid Tumor

#SolidTumor#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 85Status Active
CGTLimited DatastaleArtiva Biotherapeutics, Inc.Phase 1

NK cells/Combined Monoclonal Antibodies (NK cells/Combined Monoclonal Antibodies)

Hematological Malignancies · Hematological Malignancies

#HematologicalMalignancies#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 48Status Recruiting
CGTLimited DatastaleAdaptimmunePreclinical

Genetically engineered T Cell Receptors (Genetically engineered T Cell Receptors)

Solid and Hematological Malignancies · Solid and Hematological Malignancies

#SolidandHematologicalMalignancie#CGT#Preclinical#cell-gene-therapy#CAR-T+2
Trials 30Status Discontinued
CGTLimited DatastaleFate TherapeuticsPreclinical

Genetically engineered NK cells (Genetically engineered NK cells)

Hematological Malignancy · Hematological Malignancy

#HematologicalMalignancy#CGT#Preclinical#cell-gene-therapy#CAR-T+2
Trials 17Status Discontinued
AntibodyLimited DatastaleAntengene Therapeutics LimitedPhase 1

nivolumab (Opdivo, ATG-017+Nivolumab)

Solid Tumor; Hematological Malignancy · Solid Tumor

#SolidTumor#Antibody#Phase1#monoclonal-antibody#HematologicalMalignancy+1
Trials 1Status Discontinued
CGTLimited DatastaleInstitute of Hematology & Blood…Phase 2

Anti-CD7 CAR-T (Anti-CD7 CAR-T)

Hematological Malignancies · Hematological Malignancies

#HematologicalMalignancies#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleM.D. Anderson Cancer CenterPhase 2

C9/CD5CAR/IL-15 NK cells (C9/CD5CAR/IL-15 NK cells)

Hematological Malignancies · Hematological Malignancies

#HematologicalMalignancies#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleChang YingjunPhase 2

CD19-BCMA dual nanobody based CAR-T Cells (CD19-BCMA dual nanobody based CAR-T Cells)

Transplantation Candidates With Hematological Diseases · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleHe HuangPhase 1

CD20/CD22 dual Targeted CAR T-cells (CD20/CD22 dual Targeted CAR T-cells)

Relapsed and Refractory; Lymphoid Hematological Malignancies · CD20

#CD20#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleHe HuangPhase 2

GC022F CAR-T cells (GC022F CAR-T cells)

Relapsed and Refractory; Lymphoid Hematological Malignancies · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleLakefront Biotherapeutics NVPhase 3

GLPG CAR T-cell therapy (GLPG CAR T-cell therapy)

Hematological Malignancies · Hematological Malignancies

#HematologicalMalignancies#CGT#Phase3#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
AntibodyLimited DatastaleChinese PLA General HospitalPhase 2

metoprolol, infliximab, etanercept, tocilizumab and/or other agents (metoprolol, infliximab, etanercept, tocilizumab and/or other agents)

Solid Tumor; Hematological Malignancy · Solid Tumor

#SolidTumor#Antibody#Phase2#monoclonal-antibody#HematologicalMalignancy+1
Trials 1Status Active